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urosemide in the Long-Term
anagement of Heart Failure
he Good, the Bad, and the Uncertain*
arl T. Weber, MD, FACC
emphis, Tennessee
hen it was introduced some 35 years ago, furosemide, a
otent loop diuretic, altered the practice of medicine.
dministered intravenously, it provided a rapid natriuresis
nd diuresis that proved lifesaving to persons with acute
ulmonary edema. It eliminated the need for rotating
ourniquets and phlebotomy. Furosemide was next incorpo-
ated into the long-term management of heart failure,
here its efficacy (and safety) would be presumed but never
ystematically addressed. It is entrenched in today’s sug-
ested standard of care for chronic cardiac failure. The aim
f this commentary is to overview its use while raising
wareness of potential adverse effects.
See page 1307
ONGESTIVE HEART FAILURE
CHF) AND FUROSEMIDE (THE GOOD)
ongestive heart failure is a clinical syndrome based on a
onstellation of signs and symptoms that arise from con-
ested organs and hypoperfused tissues. Its appearance is
ooted in a salt-avid state, where Na retention (e.g.,
rinary Na/K 1.0) is based on an activation of the
irculating renin-angiotensin-aldosterone system (RAAS),
hose effector hormones overwhelm the action of natri-
retic peptides (1). When Na retention exceeds Na
xcretion, intravascular volume rises followed by an expan-
ion of extravascular volume to collectively eventuate in
igns and symptoms of CHF. In patients with untreated
HF, plasma and extracellular volumes are each increased
y 30%, whereas plasma renin activity and aldosterone
ALDO) are 5 times control values (2). Patients with
ntreated CHF or those with treated but persistent CHF
annot be euvolemic. Euvolemic patients who report exer-
ional dyspnea after climbing several flights of stairs do not
ave CHF. Furosemide is used in patients with CHF to
nhance urinary Na excretion with the target of reestab-
ishing and maintaining Na balance and euvolemia.
Integral to the safe use of furosemide in CHF is the
egular surveillance of serum electrolytes, including Mg2.
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Division of Cardiovascular Diseases, University of Tennessee Healthmcience Center, Memphis, Tennessee.erum K should be maintained between 4.0 and 5.0 mEq/l
hile Mg2 at 2.0 mEq/l. A small oral dose of spirono-
actone (25 mg) in combination with furosemide minimizes
he risk of hypokalemia and hypomagnesemia. The utility of
pironolactone, an ALDO receptor antagonist, in combina-
ion with furosemide and an angiotensin-converting enzyme
ACE) inhibitor, has proven efficacy in reducing morbid
nd mortal events in heart failure (3). However, this
egimen must only be used when renal function is not
ignificantly impaired (i.e., serum creatinine of2.0 mg/dl).
y monitoring electrolytes regularly and eliminating sup-
lemental K, the potential for hyperkalemia is minimized.
n the Studies Of Left Ventricular Dysfunction (SOLVD)
nd compared with other diuretics, K-sparing diuretics
ere associated with reduced risk of death from or hospi-
alization for progressive heart failure or all-cause
ardiovascular-related death (4).
Not all patients with left ventricular systolic and/or
iastolic dysfunction have RAAS activation and, hence,
hey can be asymptomatic, or compensated, without urinary
a retention (Na/K ratio1.0). Indeed, resting plasma
enin activity is normal in persons without signs and
ymptoms of CHF despite reduced ejection fraction (EF)
5). However, such persons are salt-sensitive with an inabil-
ty to adequately excrete a dietary salt load secondary to
educed renal vasodilator and functional reserves (6). This
xquisite sensitivity may be related to auto-/paracrine prop-
rties of angiotensin (Ang)-II produced within the kidneys
nd/or to impaired responsiveness to natriuretic peptides.
n exaggerated activation of the RAAS during upright
hysical activity (7) would adversely influence urinary Na
xcretion throughout the day despite normal resting plasma
enin. An ACE inhibitor overcomes this salt sensitivity.
ngiotensin-converting enzyme inhibition is a proven stan-
ard of care for asymptomatic and symptomatic persons
ith left ventricular systolic dysfunction.
In chronic cardiac failure, reduced EF neither predicts
ardiac output nor that fraction of systemic blood flow
pportioned to the kidneys. Accordingly, EF gauges neither
enal blood flow nor RAAS activation and, therefore, it does
ot predict the clinical severity of failure, the presence of
HF, or the need for a diuretic. This is evidenced by
atients enrolled in the SOLVD, where all patients had an
F 35%: those randomized to the prevention arm of the
rial were asymptomatic, and those enrolled in the treatment
rm were symptomatic.
Despite ACE inhibition, excessive dietary salt in a
alt-sensitive individual may mandate the short-term use of
r a larger-than-usual dose of furosemide to maintain or
eestablish euvolemia. Other such circumstances arise when
arked RAAS activation occurs with prolonged ambulation
r with upright posture in the setting of high ambient
emperatures, where skeletal muscle and cutaneous vasodi-
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September 15, 2004:1308–10 Editorial Commenteceive 20% of cardiac output. With the reduction in
ystemic blood flow that accompanies heart failure, its
nhanced apportionment to skeletal muscle and skin occurs
t the expense of renal perfusion and leads to RAAS
ctivation. The long-term use of furosemide and short-term
djustments in furosemide dosage in each individual patient
ust be determined by the physician’s clinical judgment.
OTENTIAL ADVERSE EFFECTS OF
UROSEMIDE (THE BAD AND THE UNCERTAIN)
AAS activation. Angiotensin-converting enzyme inhibi-
ion attenuates but does not eliminate the formation of and
ssociated biologic activity of circulating RAAS effector
ormones. Recurrent elevations in plasma Ang-II occur
hrough mechanisms independent of ACE whereas adrenal
LDO production is regulated by factors other than Ang-II
1). Used in excessive dosage, furosemide can cause a
ontraction of intravascular volume, the hemodynamic sig-
al accounting for RAAS activation, together with a reduc-
ion in compensatory natriuretic peptides. Plasma renin
ctivity was increased in a subset of asymptomatic patients
nrolled in the SOLVD who were receiving a diuretic (5).
he introduction of diuretics in previously untreated, euv-
lemic patients without CHF who report exertional dyspnea
this is not CHF) leads to intravascular volume contraction
nd RAAS activation at rest and during exercise (8), which
hould normalize after furosemide withdrawal.
rinary Mg2 and Ca2 excretion. In addition to pro-
oting the excretion of Na, K, and Cl that can lead to
hypokalemic, hypochloremic metabolic alkalosis, less well-
ecognized properties of furosemide include its augmenta-
ion of urinary Mg2 and Ca2 excretion. The majority of
g2 resorption occurs within the kidneys. A large fraction
f Mg2 is passively transported in the cortical thick
scending limb of Henle. Furosemide interferes with Mg2
esorption, as well as Ca and phosphate transport. Aldo-
terone also promotes Mg2 and Ca2 excretion at target
issues that include kidney and colon (9,10). When the
ypermagnesuria and hypercalciuria that accompany
hronic elevations in plasma ALDO (inappropriate for
ietary Na intake) are sustained, a loss of bone mineral
ensity could ensue. Together, furosemide-mediated and
LDO-mediated increments in urinary Mg2, Ca2, and
hosphate excretion could therefore have far-reaching ef-
ects on systemic tissues (vide infra).
The CHF syndrome is accompanied by a systemic illness
hat features oxi/nitrosative stress; a “storm” of such circu-
ating proinflammatory cytokines as interleukin-6 and tu-
or necrosis factor-alpha; and a progressive wasting of lean
issue, fat, and bone mass that eventuates in cardiac cachexia
11). Neurohormonal activation may be solely responsible
or this disorder. It is uncertain whether furosemide is
ontributory. Furosemide-induced urinary Ca2 excretion
ould lead to a reduction in ionized Ca2, which activates
he parathyroids to produce parathyroid hormone (PTH). iarathyroid hormone, in turn, stimulates the kidneys to elab-
rate 1,25(OH)2D3, an active metabolite of vitamin D. To-
ether, these hormones seek to preserve plasma Ca2 ho-
eostasis through the respective increased resorption of Ca2
rom bone and increased gastrointestinal absorption of Ca2.
one loss can be a consequence of this scenario. Moderate and
arked reductions in bone mineral density, respectively ex-
ressed as osteopenia and osteoporosis, together with elevated
TH, are found in patients with advanced symptomatic heart
ailure awaiting cardiac transplantation and having a history of
ong-term furosemide usage (11,12).
ntracellular cations. Another potential adverse outcome
o furosemide-induced urinary Mg2 and Ca2 excretion is
reduction in cytosolic free Mg2 ([Mg2]i), the biologi-
ally active component of this all-important intracellular
ivalent cation, that leads to intracellular Ca2 loading and
nduction of oxi/nitrosative stress. In peripheral blood
ononuclear cells (i.e., circulating lymphocytes and mono-
ytes), a reduction in [Mg2]i with Ca
2 loading contrib-
tes to an activation of these cells and a proinflammatory
ascular phenotype of the coronary and systemic vasculature
13–15). In the case of the heart, the resultant perivascular/
nterstitial fibrosis serves as substrate for abnormal vasomotor
eactivity, arrhythmias, and ventricular dysfunction. Fibrous
issue, its cellular composition, and their expression of bone
orphogenic proteins, together with PTH-mediated and
,25(OH)2D3-mediated mobilization of Ca
2 from bone and
ut, respectively, may predispose to tissue calcification.
ephrocalcinosis is known to accompany furosemide treat-
ent. Chronic, inappropriate (relative to dietary Na) levels of
lasma ALDO are accompanied by increased urinary Ca2
nd Mg2 excretion and parathyroid hypersecretion (9,10,16).
Aldosterone and furosemide therefore could have additive
ffects that contribute to the progressive nature of CHF. In
his issue of the Journal, McCurley et al. (17) report on a
andomized controlled (vs. saline) trial with intramuscular
urosemide (1 mg/kg) conducted in a porcine model of rapid
acing-induced ventricular dysfunction. Furosemide was
nitiated coincident with the onset of pacing and when
nimals were euvolemic and without CHF. This regimen
ccelerated the appearance of contractile and metabolic
eatures of heart failure. Included was a reduction in
chocardiographic left ventricular fractional shortening to
mplicate impaired myocardial contractility that was evident
t week 3 of pacing (vs. week 5 in placebo controls). Unlike
ontrols, there appeared an early (week 2) and persistent
levation in plasma ALDO, which could interfere with
yocardial norepinephrine reuptake (18) and over the
ourse of time reduce ventricular shortening. Moreover,
nd as noted earlier, ALDO promotes iterations in
ntracellular and extracellular concentrations of Mg2 and
a2 that perturb enzymatic reactions they regulate. For
xample, [Mg2]i inhibits a Na
/Ca2 exchanger. In the
urosemide-treated group of pigs, where urinary Mg2 is
ikely increased and ALDO/Na would reduce [Mg2]i,
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Editorial Comment September 15, 2004:1308–10solated cardiomyocytes together with a blunted responsive-
ess to isoproterenol despite elevations in plasma norepi-
ephrine that were comparable with placebo-treated ani-
als. These findings led the authors to implicate inefficient
ardiomyocyte Ca2 cycling. This important study draws
ttention to the potential detrimental effects of using a
otent loop diuretic in the setting of normal intravascular
nd extravascular volumes.
hiamine deficiency. Thiamine deficiency is another fac-
or that can contribute to a reduction in myocardial con-
ractility during furosemide treatment. It occurs through a
onspecific, flow-dependent urinary excretion of vitamin
1. This applies to usual daily doses of furosemide. More
han 90% of patients receiving at least 80 mg and 50%
eceiving 40 mg were found to have laboratory evidence of
hiamine deficiency (19). Supplemental thiamine corrects
his deficiency and improves echocardiographic EF (20).
LOSING REMARKS
oop diuretics, such as furosemide, can be lifesaving for the
erson with acute pulmonary edema. Their judicious long-
erm use can prove effective in achieving euvolemia in the
alt-avid individual. However, these potent agents have
ever been systematically validated as safe and efficacious in
he long-term management of chronic cardiac failure.
It must be recognized that such agents can do harm. For
xample, furosemide-mediated hypermagnesuria and hyper-
alciuria, when sustained, could have profound effects on the
ntracellular concentrations of these cations and all-
mportant biologic reactions and responses they govern in
uch diverse tissues as the heart, immune system, and bone.
ould it be that in seeking to preserve extracellular Mg2
nd Ca2 homeostasis in this setting, the accompanying
levations in circulating PTH and 1,25(OH)2D3 lead to a
ystemic illness that features the induction of oxi/nitrosative
tress, a proinflammatory cytokine phenotype, and a wasting
f tissues, including bone? Could this illness be rooted in
econdary hyperparathyroidism? In turn, would these calcitro-
hic hormones contribute to the progressive nature and inex-
rable downhill clinical course that can accompany chronic
ardiac failure? Is it possible that regimens involving putatively
afer, non-loop diuretics would prove effective in maintaining
uvolemia in salt-sensitive and salt-avid persons?
Investigator-initiated, hypothesis-driven research con-
ucted in a mode of discovery, such as that reported herein
y McCurley et al. (17), holds the promise to answering
hese and other questions.
eprint requests and correspondence: Dr. Karl T. Weber,
ivision of Cardiovascular Diseases, University of Tennessee
ealth Science Center, Room 353 Dobbs Research Institute, 951
ourt Avenue, Memphis, Tennessee 38163. E-mail: KTWeber@
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